catheter designed News
-
Imperative Care Announces FDA Clearance of Initial Products
Imperative Care, Inc., a company singularly dedicated to finding answers to unsolved problems in stroke, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its first family of access catheters, designed to deliver interventional treatments during minimally invasive neurovascular procedures for aneurysms, stroke and other brain blood vessel conditions. “Recognizing ...
-
Imperative Care Announces $85 Million Series C Financing for Innovative Stroke Treatments
Imperative Care, Inc. today announced that it has completed the initial closing of a Series C financing of $85 million to support the commercial launch of the company’s portfolio, which is composed of the latest advances in neurovascular devices treating ischemic and hemorrhagic strokes. The round was co-led by new investors Ally Bridge Group and Bain Capital Life Sciences. Existing ...
-
Adagio Medical Announces Publication of Cryocure-2 Data Reporting 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Discusses Current Status of iCLAS Cryoablation System
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the publication of the results of its Cryocure-2 ultra-low temperature cryoablation (ULTC) study in patients with AF in the Journal of American College of Cardiology (JACC), Clinical Electrophysiology.1 The study prospectively enrolled 79 patients at ...
-
Imperative Care Announces U.S. Clearance of the ZOOM Aspiration System
Imperative Care, Inc., a company singularly dedicated to answering unsolved problems in stroke, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ZOOM™ Aspiration System – a family of products designed to facilitate clot removal during ischemic stroke. The ZOOM Aspiration System includes the ZOOM Reperfusion Catheters, ZOOM Aspiration ...
-
Infuseon Therapeutics, Inc. CMO Discusses Delivery of Therapeutics Directly to the Brain at NeuroTech Investing and Partnering Conference
infuseon therapeutics, Inc., the company that enables therapeutic delivery to the brain, announces that Dr. Michael A. Vogelbaum, Chief Medical Officer and co-inventor of the Cleveland Multiport Catheter system, will be speaking at the NeuroTech Investing and Partnering Conference taking place in Boston on Thursday, April 7. Dr. Vogelbaum, a brain surgeon at Cleveland Clinic, will be part of the ...
-
First-in-Human Use of ReFlow for Treatment of Hydrocephalus
Anuncia, Inc., a privately-held company focused on better treatment of hydrocephalus and cerebrospinal fluid dysfunctions, announced, today, the successful first-in-human implantation of its Alivio ReFlow™ Ventricular System for treatment of hydrocephalus at Boston Children’s Hospital. This announcement comes on the heels of receiving the EU CE Mark and US FDA Clearance of Alivio ...
-
Shockwave Medical Announces Global Launch of New Peripheral Intravascular Lithotripsy Catheter
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the global commercial availability of the Shockwave M5+ peripheral IVL catheter after receiving both CE Mark and U.S. Food and Drug Administration (FDA) clearance. The Shockwave M5+ catheter, which has been in limited launch ...
-
Infuseon Therapeutics Earns FDA Clearance for Novel Central Nervous System Delivery Device
Infuseon Therapeutics’ novel central nervous system deliver device has received FDA 510(k) clearance as a therapeutic delivery device. Infuseon Therapeutics’ Cleveland Multiport CatheterTM (CMC), a multiport convection-enhanced delivery catheter, was designed by neurosurgeon Michael Vogelbaum, MD, PhD, from Cleveland Clinic’s Brain Tumor and NeuroOncology Center and Department ...
-
JenaValve Technology Welcomes Jane Metcalf as Vice President, Regulatory Affairs and Quality
JenaValve Technology, Inc., developer and manufacturer of differentiated pericardial transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, announces the appointment of Jane Metcalf toVice President, Regulatory Affairs and Quality, effective immediately. Ms. Metcalf comes to JenaValve with over 30 years of experience in themedical device industry ...
-
Imperative Care Announces First Patient Enrolled in the Imperative Trial Evaluating the Zoom 88 Large Distal Platform for the Treatment of Ischemic Stroke
Imperative Care, Inc. announced today that the first patient has been enrolled in the Imperative Trial. This prospective, multi-center clinical trial is the first study designed to evaluate the clinical benefits of direct aspiration for the treatment of ischemic stroke with the Zoom 88 Large Distal Platform, which is currently FDA cleared for neurovascular access. Additionally, the trial will ...
-
Q’Apel Medical Launches Armadillo – A New Radial Artery Access Platform to Meet the Needs of Physicians and Patients
Nationally there is a trend moving towards radial artery access versus femoral artery access for endovascular procedures and Q’Apel Medical is leading the way. Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today the launch of the Armadillo Radial Access ...
-
Adagio Medical Announces First-In-Human Use and Initiation of Multi-Center Study of Ultra-Low Temperature Cryoablation for Treatment of Recurrent Ventricular Tachycardia, Opening New Possibilities for High-Risk Patients
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced successful first-in-human use of ultra-low temperature cryoablation (ULTC) for the treatment of monomorphic VT. The two-hour mapping and ablation procedure was performed by Dr. Tom De Potter, MD, Associate Director, Cardiovascular Center ...
-
Alcyone Lifesciences Completes Spin-Off of Hydrocephalus Business, Anuncia
Alcyone Lifesciences, Inc., a privately-held company focused on transforming disease modifying therapies for central nervous system (CNS) disorders today announced the separation and spin-off of its Hydrocephalus business. The new company, known as Anuncia, Inc., is an independent company focused on better treatment of Hydrocephalus and cerebrospinal fluid dysfunctions. The separation and ...
-
Christie Medical Holdings, Inc., & B. Braun Medical Announce Collaboration Aimed at Improving Peripheral IV Access Success
Christie® Medical Holdings, Inc., with its market-leading vein finder technology, VeinViewer® system, today announced an alliance with B. Braun Medical Inc., a leader in infusion therapy and pain management. Intravenous (IV) therapy plays a central role in patient care with as many as 90 percent of hospital patients receiving a peripheral IV catheter as part of their treatment plan. Many ...
-
Procyrion, Inc. Wins Best Overall Medical Device Product in 2018 Medtech Breakthrough Awards
Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, today announced that its AortixTM device won the MedTech Breakthrough Award for "Best Overall Medical Device Product." MedTech Breakthrough is an independent organization that recognizes the top companies, technologies and products in the global health and medical ...
-
This year`s Medical Innovation Summit will highlight neurosciences innovation
Thousands of researchers, investors, entrepreneurs and those who are simply curious will descend upon the Cleveland Convocation Center October 26-28 for Cleveland Clinic Innovations Medical Innovation Summit. This year’s theme, The Neurosciences: Memory. Mood. Movement, will cover all aspects of the human brain and how it functions and malfunctions. “This is our marquee event,” ...
-
JenaValve Technology Receives CE Mark for its Trilogy TAVI System for the Treatment of Aortic Regurgitation and Aortic Stenosis
JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve implantation (TAVI) systems (also referred to as TAVR, or transcatheter aortic valve replacement) for the treatment of aortic valve disease, today announced that it has received CE Mark for its TrilogyTM Heart Valve System for the treatment of both aortic regurgitation (AR), also known as aortic ...
-
Medical Device Company Procyrion, Inc. Hires Three to Support Growth; Continues to Build
Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, announced today it has hired three additional team members to support the advancement of its intra-aortic heart pump, AortixTM, for use in NYHA Class III-IV heart failure patients. Patricia DaSilva, Margo Fendrich, and Aaron Stone will focus on product development and ...
-
Nipro Medical Corporation announces the creation of Vascular Division in the U.S.
Nipro Medical Corporation (NMC), a leading Renal, Medical, Surgical, and Interventional Radiology products manufacturer, announces the creation of a Vascular Division in the U.S. The division will include several cutting-edge technologies, innovative vascular and cardiovascular products to provide clinicians with procedural and imaging solutions that enhance patient care. To support the new ...
-
SKI Vascular Center is First Ambulatory Surgical Center in the Nation to Utilize FDA-Approved Ellipsys System for Non-Surgical Dialysis Fistula Creation
Tempe-based interventional nephrologists Randy Cooper, MD and Umar Waheed, MD, and their team at SKI Vascular Center, this week became the first ambulatory surgical center in the US to create a percutaneous arteriovenous fistula (AVF), using the Ellipsys® Vascular Access System, a game-changing innovation for patients with End-Stage Renal Disease (ESRD). The recently FDA-approved Ellipsys ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you